Miglustat

證據等級: L5

預測適應症: 10 個

Using the txgnn-pipeline skill as context. Now generating the report based on the Evidence Pack, with Tay-Sachs disease (rank 7 in the predicted list) as the primary focus — it is the only indication with meaningful clinical evidence (L2, 5 trials, 20 publications), making it the actionable candidate.

Miglustat: From Gaucher Disease to Tay-Sachs Disease

One-Sentence Summary

Miglustat (Zavesca®) is an oral substrate reduction therapy originally approved for type 1 Gaucher disease, acting by inhibiting glucosylceramide synthase (GCS) to reduce glycosphingolipid production in lysosomally stressed cells. The TxGNN model predicts it may be effective for Tay-Sachs disease (GM2 gangliosidosis), supported by 5 clinical trials and 20 publications. While the mechanistic rationale is scientifically compelling, Phase 3 trials in the infantile form were terminated early — the most realistic opportunity lies in the late-onset variant, where residual enzyme activity gives SRT more room to work.

Quick Overview

Item	Content
Original Indication	Type 1 Gaucher disease (per published literature; no Italy marketing authorization on record)
Predicted New Indication	Tay-Sachs disease
TxGNN Prediction Score	99.75%
Evidence Level	L2
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Miglustat is a small-molecule iminosugar that inhibits glucosylceramide synthase (GCS), the first committed enzyme in glycosphingolipid biosynthesis. Rather than replacing a deficient enzyme, it works as a substrate reduction therapy (SRT): by slowing the rate at which substrate is produced, it reduces the lysosomal burden to a level where residual enzyme activity can maintain metabolic balance.

Tay-Sachs disease is caused by deficiency of β-hexosaminidase A (HexA, encoded by HEXA), which normally degrades GM2 ganglioside in lysosomes. Without functional HexA, GM2 accumulates relentlessly in neurons, driving progressive neurodegeneration. Since GM2 is synthesized downstream of glucosylceramide in the sphingolipid pathway, GCS inhibition by miglustat reduces the upstream supply of GM2 precursors — directly targeting the accumulation cascade that HexA can no longer resolve.

This is precisely the same mechanistic principle behind miglustat's approved use in Gaucher disease, where glucocerebrosidase deficiency leads to glucosylceramide storage. Both Gaucher disease and Tay-Sachs are lysosomal storage disorders caused by defects in glycosphingolipid catabolism enzymes, making the SRT concept mechanistically transferable. The critical clinical distinction is that late-onset Tay-Sachs (with residual HexA activity and slower accumulation) represents a far more tractable target than the acute infantile form, where near-complete enzyme deficiency and rapid disease progression make SRT insufficient on its own.

Formal MOA data from DrugBank was not available for this report. The mechanistic analysis above is derived from published literature contained in the evidence pack.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00418847	Phase 2	Completed	5	PK and tolerability of miglustat in juvenile GM2 gangliosidosis; confirms CNS drug penetration but sample is too small for efficacy conclusions
NCT00672022	Phase 3	Completed	10	PK and safety in infantile GM2 gangliosidosis (Tay-Sachs/Sandhoff); establishes dosing feasibility but not designed to assess efficacy
NCT03822013	Phase 3	Terminated	30	Miglustat efficacy in infantile Sandhoff/Tay-Sachs — terminated early; significant negative signal for the infantile phenotype
NCT02030015	Phase 4	Terminated	16	Syner-G trial: miglustat + ketogenic diet in gangliosidoses — terminated early; combination strategy remains unresolved
NCT07399704	Phase 2	Recruiting	21	Long-term safety of Nizubaglustat (AZ-3102) in GM2/NPC; includes cohort transitioning from stable miglustat — signals active next-generation SRT competition

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19346952	2009	RCT (Phase 2)	Genetics in Medicine	12-month RCT + 24-month extension evaluating miglustat safety and efficacy in late-onset GM2 gangliosidosis (Tay-Sachs/Sandhoff); primary evidence base for this indication
37209042	2023	Systematic Review	European Journal of Neurology	Comprehensive systematic review of miglustat in GM2 gangliosidosis; results inconsistent across studies — overall mixed efficacy picture
32867370	2020	Review	Int J Molecular Sciences	Clinical features, pathophysiology, and current therapeutic options across all GM2 gangliosidoses; useful disease overview
30524313	2018	Review	Frontiers in Physiology	Emerging therapeutic approaches for Tay-Sachs including SRT, gene therapy, and enzyme enhancement — SRT positioned as bridge therapy
12808890	2003	Drug Profile Review	Curr Opin Investigational Drugs	Early miglustat drug profile; documents original Gaucher approval and early-stage Tay-Sachs/Fabry/NPC development program
16434676	2006	Case Series	Neurology	Miglustat SRT in 2 infantile TSD patients; neurological deterioration not arrested, but CSF drug exposure confirmed — supports CNS access, not infantile efficacy
28476546	2017	Observational	Mol Genetics and Metabolism	Natural history of infantile GM2 gangliosidoses; notes miglustat limited by gastrointestinal side effects — relevant tolerability signal
33738443	2021	Cohort/Multi-disease	Brain Communications	Acetyl-leucine in lysosomal storage disorders including GM2 gangliosidosis; context for combination therapy approaches with SRT
18618288	2008	Pilot Study	J Inherited Metabolic Disease	Neurocognitive testing in late-onset Tay-Sachs as a potential outcome measure; informs trial design for future miglustat studies
9572057	1998	Basic Science Review	Molecular Medicine Today	Foundational biology of GM2 gangliosidoses and rationale for substrate reduction strategies; historical scientific basis

Italy Market Information

Miglustat holds no marketing authorization in Italy. No product licenses are on record.

For reference: In other EU member states, miglustat (Zavesca®, Actelion/Janssen) is authorized for type 1 Gaucher disease in patients for whom enzyme replacement therapy is unsuitable, and for Niemann-Pick type C disease. Any repurposing application in Italy would need to proceed via AIFA's orphan drug or off-label access pathways.

Safety Considerations

No formal safety data was retrieved for this report (package insert warnings and drug interaction database both returned no results).

Based on published literature within the evidence pack:

Gastrointestinal effects: Diarrhea, flatulence, and abdominal pain are the most commonly reported adverse events; these have been significant enough to limit dosing in pediatric gangliosidosis patients.
Neurological effects: Tremor has been reported; warrants monitoring in a neurodegenerative disease context.

Please refer to the Zavesca® Summary of Product Characteristics (SmPC) for the complete safety profile before any clinical or prescribing decision.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic basis for miglustat in Tay-Sachs disease is scientifically sound and directly analogous to its approved use in Gaucher disease — both are lysosomal glycosphingolipid storage disorders amenable to substrate reduction. A completed Phase 2 RCT and a 2023 systematic review provide real clinical evidence, though results are inconsistent and largely confined to the late-onset phenotype. The infantile form is not a viable target given premature Phase 3 termination.

To proceed, the following is needed:

Specify the target population: Clinical development should focus exclusively on late-onset (juvenile/adult) Tay-Sachs, where residual HexA activity and slower accumulation make SRT mechanistically feasible; infantile Tay-Sachs has negative Phase 3 evidence (NCT03822013 terminated)
Fill DG001: Obtain TFDA/AIFA package insert warnings and contraindications before any safety evaluation can advance to S1
Fill DG002: Retrieve full MOA data from DrugBank for complete mechanistic dossier
Assess competitive landscape: Nizubaglustat (AZ-3102, NCT07399704) is actively recruiting as a next-generation SRT and may supersede miglustat in this space
Define outcome endpoints: Neurocognitive and neurological stability measures (informed by PMID 18618288) should anchor any prospective study design
Regulatory pathway: Evaluate feasibility of AIFA orphan drug designation or Law 648 access prior to initiating any Italian-specific program
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.